Targeted radiation therapy for advanced Hurthle cell thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a targeted radioactive treatment (called 177Lu-DOTA-EB-TATE) for people with Hurthle cell thyroid cancer that has spread and is no longer responding to standard radioactive iodine therapy. The aim is to see if this treatment can slow or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have Hurthle cell (oncocytic) thyroid cancer that has spread to other parts of the body and did not respond to or absorb radioactive iodine (RAI) treatment.
- Your cancer must have shown signs of growing in the last 12 months, as seen on scans.
- A special PET scan (DOTATATE) must show high levels of a protein (SSTR2) on at least one of your cancer spots.
- You cannot have serious kidney, liver, or bone marrow problems, and you need to be generally able to care for yourself (Karnofsky score 70% or higher).
- You cannot be pregnant or breastfeeding, and you must be willing to use effective birth control during the study and for a few months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have or may have thyroid nodules (lumps in the thyroid gland in your neck) or thyroid cancer, as well as family members who may have inherited a higher risk. It aims to better understand and diagnose these thyroid problems.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
This trial tests a new type of PET scan (F-18 Tetrafluoroborate) to find thyroid cancer cells that don't show up on standard scans. It's for people who have had surgery and radioactive iodine therapy but still have signs of cancer in their blood tests.
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.